Patients regain much weight after stopping new obesity drug: Study

Sufferers regain a lot weight after stopping new weight problems drug: Research

That is a picture of a weight scale. Credit score: CDC/Debora Cartagena

A brand new era of weight problems medicine typically delivers dramatic weight reduction, however many sufferers marvel what occurs after they cease remedy.

One research printed Monday within the Journal of the American Medical Affiliation gives a solution: a lot of the load comes again, signaling sufferers could also be locked into long-term dependence on the medicine.

The analysis was primarily based on weekly injections of tirzepatide, the compound in Eli Lilly’s new weight reduction drug Zepbound that was accepted by the US final month.

After 36 weeks, 670 adults achieved a notable imply weight lack of 20.9 p.c.

The group was then cut up into two, with half persevering with on Zepbound, and the opposite half given a placebo.

At 88 weeks, these on the placebo regained nearly half of the load they’d misplaced, ending up 9.9 p.c decrease than their baseline.

These on Zepbound continued to drop extra pounds, ending 25.3 p.c decrease than the place they’d began.

The trial sufferers have been largely ladies and had a imply age of 48, with a imply weight on the outset was 107.3 kilograms (236.6 kilos).

All members have been inspired to eat 500 energy much less every day than they burnt and take not less than 150 minutes of train per week.

Widespread uncomfortable side effects have been gastrointestinal points together with nausea, diarrhea, constipation and vomiting, mentioned the research.

Rising proof

Research authors, led by Louis Aronne at Weill Cornell Medication, New York, mentioned the outcomes “emphasize the necessity to proceed pharmacotherapy to stop weight regain and make sure the upkeep of weight discount.”

They added the newest analysis provides to 4 earlier trials that confirmed “medicines, together with potent antiobesity medicines equivalent to semaglutide, have demonstrated that weight is considerably regained” after stopping remedy.

Semaglutide is the lively ingredient in Novo Nordisk’s Ozempic and Wegovy, which, like Zepbound, are examples of so-called “GLP-1 agonists” that work by mimicking the perform of a hormone that secretes insulin, slows down the emptying of the abdomen, and suppresses urge for food.

Zepbound additionally accommodates one other molecule that acts just like the intestine hormone GIP.

In response to the research, Lilly’s Jeff Emmick mentioned in an announcement that “sufferers, suppliers and the general public don’t all the time perceive weight problems is a persistent illness that always requires ongoing remedy, which might imply that remedy is stopped as soon as weight objectives are met.”

GLP-1 agonists have been discovered to chop the danger of heart problems related to weight problems—however additionally they heighten the danger of gastrointestinal issues, research present.

Although the charges of significant points equivalent to abdomen paralysis are low, some consultants worry that utilizing the medicine for years or a long time might change the benefit-to-risk calculus.

Value will also be a disincentive. Zepbound prices $1,059.87 per thirty days, and insurance coverage corporations typically don’t cowl weight reduction medicines. Medicare, state-subsidized insurance coverage for the aged, is barred from masking it.

Extra info:
Louis J. Aronne et al, Continued Therapy With Tirzepatide for Upkeep of Weight Discount in Adults With Weight problems, JAMA (2023). DOI: 10.1001/jama.2023.24945

© 2023 AFP

Sufferers regain a lot weight after stopping new weight problems drug: Research (2023, December 11)
retrieved 21 December 2023

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.

Add a Comment

Your email address will not be published. Required fields are marked *